Recent advances in intraocular drug delivery systems

Recent Patents on Drug Delivery and Formulation

Volumn 5, Issue 1, 2011, Pages 1-10

  Yasukawa, Tsutomu ^a   Tabata, Yasuhiko ^b   Kimura, Hideya ^c   Ogura, Yuichiro ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c Nagata Eye Clinic   (Japan)

Author keywords

Age related macular degeneration; Controlled release; Drug targeting; Intraocular drug delivery systems; Macularedema; Retina

Indexed keywords

AFLIBERCEPT; BETA INTERFERON; BETAMETHASONE; BEVACIZUMAB; CAPLOSTATIN; CILIARY NEUROTROPHIC FACTOR; DE 102; DEXAMETHASONE; DEXTRAN; ETHYLENE VINYL ACETATE COPOLYMER; FLUOCINOLONE ACETONIDE; FUMAGILLOL CHLOROACETYLCARBAMATE; GANCICLOVIR; ILUVIEN; INTERFERON; IVATION; MEDIDUR; MITOMYCIN C; NANOPARTICLE; NT 501; PEGAPTANIB; PENTETIC ACID; POLYGLACTIN; POLYVINYL ALCOHOL; RANIBIZUMAB; SILICONE; THALIDOMIDE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; VERTEPORFIN; IMMUNOSUPPRESSIVE AGENT; PHOTOSENSITIZING AGENT;

ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BIOCOMPATIBILITY; BIODEGRADABILITY; CATARACT; CONTROLLED DRUG RELEASE; CYTOMEGALOVIRUS RETINITIS; DIABETIC MACULAR EDEMA; DRUG ACCUMULATION; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG IMPLANT; DRUG SAFETY; DRUG SOLUBILITY; DRUG TARGETING; DRUG TOLERABILITY; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; MICELLE; NONHUMAN; PATENT; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; RETINITIS PIGMENTOSA; SOLID TUMOR; SUBRETINAL NEOVASCULARIZATION; UVEITIS; VITREORETINOPATHY; BIODEGRADABLE IMPLANT; CLINICAL TRIAL (TOPIC); DELAYED RELEASE FORMULATION; DRUG ADMINISTRATION ROUTE; INTRAOCULAR DRUG ADMINISTRATION; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; PHOTOCHEMOTHERAPY; RETINA MACULA DEGENERATION; REVIEW;

ABSORBABLE IMPLANTS; CLINICAL TRIALS AS TOPIC; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAOCULAR; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MACULAR EDEMA; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS;

EID: 79954446082     PISSN: 18722113     EISSN: 18722113     Source Type: Journal    
DOI: 10.2174/187221111794109529     Document Type: Article

References (47)

1. Maurice DM, Mishima S. Ocular Pharmacokinetics. In: Pharmacology of the Eye. In: Sears ML, Ed. New York: Springer 1984; 116-119.
2. Lang LC. Ocular drug delivery: Conventional ocular formulations. Adv Drug Deliv Rev 1995; 16: 39-43.
3. Ip MS, Gottlieb JL, Kahana A, Murdoch JR. Intravitrealtriamcinolone for the treatment of macular edema associated withcentral retinal vein occlusion. Arch Ophthalmol 2004; 122: 1131-6.
4. Gillies MC, Sutter FKP, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema.Two-year results of a double-masked, placebo-controlled,randomized clinical trial. Ophthalmology 2006; 113:1533-8.
5. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. MARINA Study Group. Ranibizumab for neovascularage-related macular degeneration. N Engl J Med 2006; 355: 1419-31.
6. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. ANCHOR Study Group. Ranibizumab versus verteporfinfor neovascular age-related macular degeneration. N Engl J Med 2006; 355:1432-1444.
7. Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy combinedwith intravitreal triamcinolone in all types of choroidalneovascularization due to age-related macular degeneration.Ophthalmology 2006; 113:14-22.
8. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis).Ophthalmology 2007; 114: 2179-82.
9. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin).Ophthalmology 2007; 114: 855-9.
10. Cantrill WH, Henry K, Melroe NH, Gastaud P. Treatment ofcytomegalovirus retinitis with intravitreal ganciclovir: Long-termresults. Ophthalmology 1989; 96: 367-74.
11. Cocherau-Massin I, Lehoang P, Lautier-Frau M, Zazoun L, Marcel P, Robinet M, et al. Efficacy and tolerance of intravitrealganciclovir in cytomegalovirus retinitis in acquired immunedeficiency syndrome. Ophthalmology 1991; 98:1348-55.
12. Heinemann MH. Long-term intravitreal ganciclovir therapy forcytomegalovirus retinopathy. Arch Ophthalmol 1989; 107: 1767-72.
13. Ussery FM, Gibson SR, Conklin RH, Piot DF, Stool EW, Conklin AJ. Intravitreal ganciclovir in the treatment of AIDS-associated cytomegalovirus retinitis. Ophthalmology 1988; 95: 640-8.
14. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.)Clinical Trial Group: D'Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET Jr, Guyer DR, et al. Pegaptanibsodium for neovascular age-related macular degeneration: Twoyearsafety results of the two prospective, multicenter, controlledclinical trials. Ophthalmology 2006; 113: 992-1001.
15. Sanborn GE, Anald R, Torti RE, Nightingale SD, Cal SX, Yates B, et al. Sustained-release ganciclovir therapy for treatment ofcytomegalovirus retinitis. Use of an intravitreal device. ArchOphthalmol 1992; 110:188-95.
16. Yasukawa T, Ogura Y, Tabata Y, Kimura H, Wiedemann P, Honda Y. Drug delivery systems for vitreoretinal diseases. Prog Retin EyeRes 2004; 23: 253-81.
17. Yasukawa T, Ogura Y, Kimura H, Sakurai E, Tabata Y. Drugdelivery from ocular implants. Expert Opin Drug Deliv 2006; 3:261-73.
18. Okabe K, Kimura H, Okabe J, Kato A, Kunou N, Ogura Y. Intraocular tissue distribution of betamethasone after intrascleraladministration using a non-biodegradable sustained drug deliverydevice. Invest Ophthalmol Vis Sci 2003; 44: 2702-7.
19. Callanan DG. Novel intravitreal fluocinolone acetonide implant inthe treatment of chronic noninfectious posterior uveitis. Expert RevOphthalmol 2007; 2: 33-44.
20. Yasukawa T, Kimura H, Kunou N, Miyamoto H, Honda Y, Ogura Y, et al. Biodegradable scleral implant for intravitreal controlledrelease of ganciclovir. Graefes Arch Clin Exp Ophthalmol 2000;238:186-90.
21. Kunou N, Ogura Y, Yasukawa T, Kimura H, Miyamoto H, Honda Y, et al. Long-term sustained release of ganciclovir from biodegradable scleral implant for the treatment of cytomegalovirusretinitis. J Control Release 2000; 68: 263-71.
22. McSwiggen, J., Beigelman, L., Macejak, D., Zinnen, S., Pavco, P., Morrissey, D., Fosnaugh, K., Mokler, V., Jamison, S. RNA interference by modified short interfering nucleic acid.WO2003070918 (2003).
23. Giese, K., Kaufmann, J., Klippel-Giese, A. Future novel forms ofinterfering RNA molecules. WO2004015107 (2004).
24. Robinson, M.R., Blanda, W.M., Hughes, P.M., Burke, J.A., Whitcup, S.M. Method for treating atrophic age related macularde generation. US20100015158 & WO2010009034 (2010).
25. Robinson, M.R., Tsai, S.Y., Almazan, A.S., Blanda, W.M., Hughes, P.M., Burke, J.A., Whitcup, S.M. Drug delivery systemsand methods for treating neovascularization. US20100098772 &WO2010048086 (2010).
26. Robinson, M.R., Blanda, W.M., Liu, H., Whitcup, S.M., Hughes, P.M. Intraocular formulation. US20100074957 (2010).
27. Lyons, R.T., Ma, H., Trogden, J.T. Methods, compositions anddrug delivery systems for intraocular delivery of siRNA molecules.US20090258924 (2009).
28. Jaffe GJ, Ben-nun J, Guo H, Dunn JP, Ashton P. Fluocinoloneacetonide sustained drug delivery device to treat severe uveitis.Ophthalmology 2000; 107: 2024-33.
29. http://www.bausch.com/en_US/ecp/general/product/ecp_retisert.aspx
30. http://www.surmodics.com/pdf/ophthalmology.pdf
31. http://www.psivida.com/products-iluvien.html
32. http://www.allergan.com/assets/pdf/ozurdex_pi.pdf
33. Pharmacological Therapy for Macular Degeneration Study Group.Interferon alfa-2a is ineffective for patients with choroidalneovascularization secondary to age-related macular degeneration.Results of a prospective randomized placebo-controlled clinicaltrial. Arch Ophthalmol 1997; 115: 865-872.
34. Ip M, Gorin MB. Recurrence of a choroidal neovascular membranein a patient with punctate inner choroidopathy treated with dailydoses of thalidomide. Am J Ophthalmol 1996; 122: 594-5.
35. Matsumura Y, Maeda H. A new concept for macromoleculartherapeutics in cancer chemotherapy: Mechanism of tumoritropicaccumulation of proteins and the antitumor agent smancs. CancerRes 1986; 46: 6387-92.
36. Yasukawa T, Kimura H, Tabata Y, Miyamoto H, Honda Y, Ikada Y, et al. Targeted delivery of anti-angiogenic agent TNP-470 usingwater-soluble polymer in the treatment of choroidalneovascularization. Invest Ophthalmol Vis Sci 1999; 40: 2690-6.
37. Yasukawa T, Kimura H, Tabata Y, Kamizuru H, Miyamoto H, Honda Y, et al. Targeting of interferon to choroidalneovascularization by use of dextran and metal coordination. InvestOphthalmol Vis Sci 2002; 43: 842-8.
38. Ideta R, Yanagi Y, Tamaki Y, Tasaka F, Harada A, Kataoka K. Effective accumulation of polyion complex micelle to experimentalchoroidal neovascularization in rats. FEBS Lett 2004; 557: 21-5.
39. Satchi-Fainaro R, Puder M, Davies JW, Tran HT, Sampson DA, Greene AK, et al. Targeting angiogenesis with a conjugate ofHPMA copolymer and TNP-470. Nat Med 2004; 10: 255-61.
40. Satchi-Fainaro R, Mamluk R, Wang L, Short SM, Nagy JA, Feng D, et al. Inhibition of vessel permeability by TNP-470 and itspolymer conjugate, caplostatin. Cancer Cell 2005; 7: 251-61.
41. Yasukawa T, Kumura H, Tabata Y, Miyamoto H, Honda Y, Ikada Y, et al. Active drug targeting with immunoconjugates to choroidalneovascularization. Curr Eye Res 2000; 21:952-61.
42. Kamizuru H, Kimura H, Yasukawa T, Tabata Y, Honda Y, Ogura Y. Monoclonal antibody-mediated drug targeting to choroidalneovascularization in the rat. Invest Ophthalmol Vis Sci 2001; 42:2664-72.
43. Friedlander M, Theesfeld CL, Sugita M, Fruttiger M, Thomas MA, Chang S, et al. Involvement of integrins alpha v beta 3 and alpha vbeta 5 in ocular neovascular diseases. Proc Natl Acad Sci USA 1996; 93: 9764-9769.
44. Wada M, Ogata N, Otsuji T, Uyama M. Expression of vascularendothelial growth factor and its receptor (KDR/flk-1) mRNA inexperimental choroidal neovascularization. Curr Eye Res 1999; 18:203-13.
45. Sakurai E, Taguchi H, Anand A, Ambati BK, Gragoudas ES, Miller JW, et al. Targeted disruption of the CD18 or ICAM-1 geneinhibits choroidal neovascularization. Invest Ophthalmol Vis Sci 2003; 44: 2743-2749.
46. Shen WY, Yu MJ, Barry CJ, Constable IJ, Rakoczy PE. Expressionof cell adhesion molecules and vascular endothelial growth factorin experimental choroidal neovascularization in the rat. Br JOphthalmol 1998; 82: 1063-71.
47. Takeda A, Baffi JZ, Kleinman ME, Cho WG, Nozaki M, Yamada K, et al. CCR3 is a target for age-related macular degenerationdiagnosis and therapy. Nature 2009; 460: 225-30.